Covered recipient · General Payments record
RUEMU E BIRHIRAY
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$402,031.80
578 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $308,096.00 | 117 |
| Travel and Lodging | $46,954.63 | 122 |
| Consulting Fee | $34,756.25 | 13 |
| Food and Beverage | $12,133.98 | 323 |
| Education | $90.94 | 3 |
By paying entity
PY2019 · entire year · sorted by reported total
Page 4 of 12; records 151–200 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
RUEMU E BIRHIRAY
NPI 1295735058 · CMS profile ID 742525
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
INDIANAPOLIS, IN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 12; records 151–200 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 12; records 151–200 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 12; records 151–200 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- RUEMU E BIRHIRAY, NPI 1295735058, CMS profile ID 742525, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 12; records 151–200 of 578 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1295735058?year=2019&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
578 matching records · $402,031.80 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 578.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $873.58 | 09/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659134829 | CMS |
| Novartis Pharmaceuticals Corporation | $3,930.00 | 09/30/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659134831 | CMS |
| Novartis Pharmaceuticals Corporation | $67.93 | 09/30/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 659134835 | CMS |
| Dova Pharmaceuticals | $6,250.00 | 09/28/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705226159 | CMS |
| Dova Pharmaceuticals | $128.61 | 09/28/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705228734 | CMS |
| Dova Pharmaceuticals | $38.55 | 09/28/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705231089 | CMS |
| Janssen Biotech, Inc. | $3,800.00 | 09/27/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658334667 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $16.46 | 09/26/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 628413483 | CMS |
| Agios Pharmaceuticals, Inc. | $15.80 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 701352367 | CMS |
| Incyte Corporation | $5,535.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269895 | CMS |
| Incyte Corporation | $125.00 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269899 | CMS |
| Merck Sharp & Dohme Corporation | $12.34 | 09/24/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695756983 | CMS |
| Puma Biotechnology, Inc. | $3,500.00 | 09/24/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017313 | CMS |
| Janssen Biotech, Inc. | $974.97 | 09/23/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658334659 | CMS |
| Janssen Biotech, Inc. | $60.65 | 09/23/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658334663 | CMS |
| Amgen Inc. | $14.09 | 09/20/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662978845 | CMS |
| Clovis Oncology, Inc. | $18.37 | 09/19/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 688690917 | CMS |
| Janssen Biotech, Inc. | $1,208.06 | 09/19/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658334656 | CMS |
| PFIZER INC. | $19.72 | 09/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673276601 | CMS |
| PFIZER INC. | $10.00 | 09/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673821397 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $121.32 | 09/18/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665709245 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $3,000.00 | 09/18/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665709247 | CMS |
| Pharmacyclics LLC, An AbbVie Company | $828.72 | 09/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 665709249 | CMS |
| Puma Biotechnology, Inc. | $1,118.81 | 09/18/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017309 | CMS |
| E.R. Squibb & Sons, L.L.C. | $10.39 | 09/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651231605 | CMS |
| Incyte Corporation | $18.55 | 09/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269825 | CMS |
| Puma Biotechnology, Inc. | $4,000.00 | 09/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017311 | CMS |
| Amgen Inc. | $1,000.00 | 09/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662978997 | CMS |
| Amgen Inc. | $3,000.00 | 09/16/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662978999 | CMS |
| Puma Biotechnology, Inc. | $75.40 | 09/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017299 | CMS |
| Puma Biotechnology, Inc. | $118.66 | 09/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017307 | CMS |
| Dova Pharmaceuticals | $5,500.00 | 09/14/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705226176 | CMS |
| Dova Pharmaceuticals | $43.20 | 09/14/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705231027 | CMS |
| Dova Pharmaceuticals | $15.66 | 09/14/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 705235487 | CMS |
| Amgen Inc. | $124.99 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662979013 | CMS |
| Incyte Corporation | $19.76 | 09/12/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269817 | CMS |
| Puma Biotechnology, Inc. | $4,500.00 | 09/11/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017357 | CMS |
| Amgen Inc. | $14.13 | 09/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 662978745 | CMS |
| Lilly USA, LLC | $9.92 | 09/10/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 658128507 | CMS |
| Puma Biotechnology, Inc. | $20.00 | 09/10/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 706017315 | CMS |
| GENZYME CORPORATION | $3,325.00 | 09/09/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 694213337 | CMS |
| Incyte Corporation | $124.03 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269877 | CMS |
| Incyte Corporation | $97.50 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269879 | CMS |
| Incyte Corporation | $216.92 | 09/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269883 | CMS |
| Incyte Corporation | $71.00 | 09/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269887 | CMS |
| Incyte Corporation | $6.52 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269889 | CMS |
| Incyte Corporation | $1.74 | 09/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 666269893 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 651231597 | CMS |
| Merck Sharp & Dohme Corporation | $17.70 | 09/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 695767291 | CMS |
| EISAI INC. | $17.65 | 09/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697040099 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $1,101.73 | 2 |
| PY2025 | Principal investigator | $302,723.74 | 30 |
| PY2024 | Recipient | $2,874.14 | 8 |
| PY2024 | Principal investigator | $157,922.00 | 27 |
| PY2023 | Principal investigator | $134,202.50 | 66 |
| PY2022 | Principal investigator | $73,428.50 | 35 |
| PY2021 | Principal investigator | $38,582.48 | 8 |
| PY2020 | Principal investigator | $53,982.71 | 20 |
| PY2019 | Principal investigator | $134,360.15 | 29 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
32 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Genentech, Inc. | $4,950.00 | 12/12/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617542 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,071.90 | 12/04/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184269329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,986.10 | 12/04/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184269331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.00 | 12/03/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) | No dispute reported | 06/30/2026 | 1184268413 |
| Principal investigator 1 | Genentech, Inc. | $7,117.00 | 11/19/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,050.00 | 11/10/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184259291 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $700.00 | 11/10/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184259293 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $250.00 | 11/10/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184259295 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $275.00 | 11/10/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184259297 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,458.60 | 11/07/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184259125 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $225.00 | 10/22/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) | No dispute reported | 06/30/2026 | 1223287155 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $196,714.04 | 10/02/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA, LLC | A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER) | No dispute reported | 06/30/2026 | 1190311149 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $835.22 | 10/02/2025 | Covered Recipient Physician | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184115711 |
| Principal investigator 1 | Genentech, Inc. | $2,250.00 | 10/01/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617535 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,287.50 | 09/18/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | C16038 (SWITCH) An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO) in Combination with Lenalidomide and Dexamethasone (IRD) in Patients with Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) | No dispute reported | 06/30/2026 | 1223285662 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $266.51 | 09/16/2025 | Covered Recipient Physician | AN OPEN-LABEL STUDY TO ASSESS THE ANTI-TUMOR ACTIVITY AND SAFETY OF REGN1979, AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | No dispute reported | 06/30/2026 | 1184115709 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $480.00 | 08/18/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF IXAZOMIB (NINLARO?) IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (IRD) IN PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY RECEIVING A BORTEZOMIB-BASED INDUCTION REGIMEN (US MM-6) | No dispute reported | 06/30/2026 | 1223284359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,402.40 | 07/31/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222880 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,346.80 | 07/31/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222882 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,039.20 | 07/31/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184222884 |
| Principal investigator 1 | Genentech, Inc. | $4,950.00 | 07/21/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617531 |
| Principal investigator 1 | Genentech, Inc. | $4,950.00 | 06/04/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617513 |
| Principal investigator 1 | Genentech, Inc. | $1,600.00 | 06/04/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617517 |
| Principal investigator 1 | Genentech, Inc. | $2,808.00 | 06/02/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617510 |
| Principal investigator 1 | Genentech, Inc. | $6,410.00 | 05/12/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617528 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,071.90 | 04/15/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184183396 |
| Principal investigator 1 | Genentech, Inc. | $9,051.00 | 04/03/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617524 |
| Principal investigator 1 | Genentech, Inc. | $9,560.00 | 03/21/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | Phase 3 Mosunetuzumab Lenalidomide in R R Follicular Lymphoma | No dispute reported | 06/30/2026 | 1211617521 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,402.40 | 03/04/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184156674 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $9,999.00 | 01/17/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184148175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,971.00 | 01/17/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184148177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,071.90 | 01/07/2025 | Non-covered Recipient Entity INVESTIGATIVE CLINICAL RESEARCH OF INDIANA LLC | A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY VERSUS INVESTIGATOR'S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1) | No dispute reported | 06/30/2026 | 1184145936 |